{
  "docId": "019de077-0326-7579-845c-ff13347b3147",
  "docSlug": "a6759fd47798a8f3f6e744ad8917865e",
  "documentTitle": "Exscientia | Investor Presentation Deck | 93 slides",
  "authorId": "exscientia",
  "authorName": "Exscientia",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 48,
  "pageCount": 93,
  "prevPage": 47,
  "nextPage": 49,
  "slideType": "roadmap",
  "function": "plan_implementation",
  "density": "dense",
  "nDataPoints": 4,
  "notes": "The slide outlines a standard oncology clinical trial design (Phase 1/2) with a transition point at RP2D (Recommended Phase 2 Dose).",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de077-0326-7579-845c-ff13347b3147/48",
  "deckHref": "/decks/019de077-0326-7579-845c-ff13347b3147",
  "deckJsonHref": "/decks/019de077-0326-7579-845c-ff13347b3147.json",
  "deckAnchorHref": "/decks/019de077-0326-7579-845c-ff13347b3147#slide-48",
  "components": [
    {
      "bbox": {
        "h": 0.45,
        "w": 0.68,
        "x": 0.24,
        "y": 0.25
      },
      "kind": "diagram",
      "text": "Two-part trial assessing safety, PK/PD and efficacy of GTAEXS617 in patients with advanced solid tumours",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a844b4b0-ee8c-4a80-8881-8b239091009f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.86,
        "x": 0.07,
        "y": 0.88
      },
      "kind": "disclaimer",
      "text": "ELUCIDATE (protocol number GTAEXS617-001) is a Phase 1/2 open-label multi-centre study to assess the safety, pharmacokinetics and anti-tumour activity of GTAEXS617 in patients with advanced solid tumours (who have failed on, refused or are ineligible for the standard of care (SoC))",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e3cab82f-aa28-455e-87cc-79d0e672a314",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.86,
        "x": 0.07,
        "y": 0.77
      },
      "kind": "paragraph",
      "text": "Additional data generation, including clinical endpoints, peripheral and tumour multi-omics, and correlation of data and response to previously collected ex vivo results planned",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "03400210-02e6-4cb8-aed3-eb8ece91bed3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.75,
        "x": 0.07,
        "y": 0.13
      },
      "kind": "title",
      "text": "Preclinically identified PD biomarkers to be further assessed in the trial",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e2a9b7d4-b17b-494d-96de-cd0e0b3e7064",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.85,
        "x": 0.07,
        "y": 0.06
      },
      "kind": "title",
      "text": "ELUCIDATE: '617 Phase 1/2 ongoing in advanced solid tumours",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a9597d0e-85f6-45ee-8931-739088a004e0",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "clinical-trial-design",
      "slug": null,
      "matchId": "00f8cdc2-e598-4e15-b04e-223b1c20a4ec",
      "evidence": "Standard oncology trial structure (Dose Escalation -> RP2D -> Dose Expansion)",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 76,
      "from": 40,
      "beatId": "5ac1e19c-a020-4b03-85c5-f8d4af660d2d",
      "arcName": "The Sparkline",
      "arcSlug": "sparkline",
      "beatName": "Traction",
      "beatSlug": null,
      "evidence": "Highlighting of Exscientia's achievements and partnerships",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}